N. Noor et al., EFFECTS OF CISAPRIDE ON SYMPTOMS AND POSTCIBAL SMALL-BOWEL MOTOR FUNCTION IN PATIENTS WITH IRRITABLE-BOWEL-SYNDROME, Scandinavian journal of gastroenterology, 33(6), 1998, pp. 605-611
Background: Irritable bowel syndrome is a common cause of abdominal pa
in and discomfort and may be related to disordered gastrointestinal mo
tility. Our aim was to assess the effects of long-term treatment with
a prokinetic agent, cisapride, on postprandial jejunal motility and sy
mptoms in the irritable bowel syndrome (IBS). Methods: Thirty-eight pa
tients with IBS (constipation-predominant, n = 17; diarrhoeapredominan
t, n = 21) underwent 24-h ambulatory jejunal manometry before and afte
r 12 week's treatment {cisapride, 5 mg three times daily (n = 19) or p
lacebo (n = 19)}. Results: In diarrhoea-predominant patients significa
nt differences in contraction characteristics were observed between th
e cisapride and placebo groups. In cisapride-treated diarrhoea-predomi
nant patients the mean contraction amplitude was higher (29.3 +/- 3.2
versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretr
eatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.
4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001)
; pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency l
ower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus place
bo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min) than patients tre
ated with placebo. No significant differences in jejunal motility were
found in the constipation predominant IBS group. Symptoms were assess
ed by using a visual analogue scale before and after treatment. Sympto
m scores relating to the severity of constipation were lower in cisapr
ide-treated constipation-predominant IBS patients {score, 54 +/- 5 ver
sus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 6
2 +/- 19 mm}. Diarrhoea-predominant IBS patients had a higher pain sco
re after cisapride therapy {score, 55 +/- 15 versus 34 +/- 12 mm, cisa
pride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm. Conclusio
n: Cisapride affects jejunal contraction characteristics and some symp
toms in IBS.